Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
About this item
Full title
Author / Creator
Raskob, Gary E , van Es, Nick , Verhamme, Peter , Carrier, Marc , Di Nisio, Marcello , Garcia, David , Grosso, Michael A , Kakkar, Ajay K , Kovacs, Michael J , Mercuri, Michele F , Meyer, Guy , Segers, Annelise , Shi, Minggao , Wang, Tzu-Fei , Yeo, Erik , Zhang, George , Zwicker, Jeffrey I , Weitz, Jeffrey I , Büller, Harry R and Hokusai VTE Cancer Investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a randomized trial, 1050 patients with cancer who had acute venous thromboembolism were assigned to receive either dalteparin or edoxaban for 6 to 12 months. Edoxaban was noninferior to dalteparin with respect to the outcome of recurrent venous thromboembolism or major bleeding.
Alternative Titles
Full title
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Authors, Artists and Contributors
Author / Creator
van Es, Nick
Verhamme, Peter
Carrier, Marc
Di Nisio, Marcello
Garcia, David
Grosso, Michael A
Kakkar, Ajay K
Kovacs, Michael J
Mercuri, Michele F
Meyer, Guy
Segers, Annelise
Shi, Minggao
Wang, Tzu-Fei
Yeo, Erik
Zhang, George
Zwicker, Jeffrey I
Weitz, Jeffrey I
Büller, Harry R
Hokusai VTE Cancer Investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2003032747
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2003032747
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1711948
